Literature DB >> 6088786

Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function.

J D Tratschin, I L Miller, B J Carter.   

Abstract

Transfection of a pBR322-based, recombinant plasmid, pAV2, containing the entire adeno-associated virus (AAV) type 2 genome into human 293 cells in the presence of helper adenovirus resulted in rescue and replication of AAV to yield infectious particles. We constructed mutants of pAV2 containing deletions within the AAV sequence. We describe here the phenotypes of these AAV deletion mutants. The results can be summarized as follows. Mutants (cap-) with deletions between map positions 53 and 85 did not synthesize capsid antigen or progeny single-stranded DNA but accumulated normal levels of duplex replicating form DNA. Mutants (rep-) with deletions between map positions 17 and 36 failed to rescue or replicate any AAV DNA. The rep- mutants could be complemented for replicating form DNA synthesis by a cap- mutant. This clearly demonstrates an AAV-coded replication function which is different from the capsid antigen. Other mutants (inf-) with deletions in the region between map positions 40 and 52 synthesized abundant amounts of replicating form DNA and capsid antigen but gave a low yield of infectious particles. This suggests that there may be an additional region of AAV, perhaps within the intron, which is required for efficient particle assembly. This work shows that AAV is genetically complex and expresses at least three clearly different functions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088786      PMCID: PMC255808     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Adeno-associated virus DNA replication.

Authors:  K I Berns; W W Hauswirth; K H Fife; E Lusby
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1979

2.  Defective-interfering particles of the human parvovirus adeno-associated virus.

Authors:  C A Laughlin; M W Myers; D L Risin; B J Carter
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

3.  Adenovirus-associated virus structural protein sequence homology.

Authors:  M D Lubeck; H M Lee; M D Hoggan; F B Johnson
Journal:  J Gen Virol       Date:  1979-10       Impact factor: 3.891

4.  Spliced adenovirus-associated virus RNA.

Authors:  C A Laughlin; H Westphal; B J Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

5.  Assembly of adeno-associated virus.

Authors:  M W Myers; B J Carter
Journal:  Virology       Date:  1980-04-15       Impact factor: 3.616

6.  Extraction of nucleic acids from agarose gels.

Authors:  J Langridge; P Langridge; P L Bergquist
Journal:  Anal Biochem       Date:  1980-04       Impact factor: 3.365

7.  Definition of a novel promoter for the major adenovirus-associated virus mRNA.

Authors:  M R Green; R G Roeder
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

8.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

9.  Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells.

Authors:  A K Cheung; M D Hoggan; W W Hauswirth; K I Berns
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

10.  Construction of an SV40-derived cloning vector.

Authors:  N Muzyczka
Journal:  Gene       Date:  1980-10       Impact factor: 3.688

View more
  128 in total

1.  Factors affecting the terminal resolution site endonuclease, helicase, and ATPase activities of adeno-associated virus type 2 Rep proteins.

Authors:  J Wu; M D Davis; R A Owens
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses.

Authors:  Jianming Qiu; Ramnath Nayak; Gregory E Tullis; David J Pintel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size.

Authors:  G E Tullis; T Shenk
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles.

Authors:  Ioannis Bossis; John A Chiorini
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  In vivo resolution of circular plasmids containing concatemer junction fragments from minute virus of mice DNA and their subsequent replication as linear molecules.

Authors:  S F Cotmore; P Tattersall
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  DNA dynamically directs its own transcription initiation.

Authors:  Chu H Choi; George Kalosakas; Kim O Rasmussen; Makoto Hiromura; Alan R Bishop; Anny Usheva
Journal:  Nucleic Acids Res       Date:  2004-03-05       Impact factor: 16.971

7.  Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein.

Authors:  A Beaton; P Palumbo; K I Berns
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  High-level expression of adeno-associated virus (AAV) Rep78 or Rep68 protein is sufficient for infectious-particle formation by a rep-negative AAV mutant.

Authors:  C Hölscher; J A Kleinschmidt; A Bürkle
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein.

Authors:  S R Kyöstiö; R S Wonderling; R A Owens
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 10.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.